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Styrene maleic acid recovers 
proteins from mammalian cells and 
tissues while avoiding significant 
cell death
Andrew J. Smith  1,2*, Kathleen E. Wright  1, Stephen P. Muench  1,3, Sophie Schumann4, 
Adrian Whitehouse3,4, Karen E. porter5 & John colyer1
Detection of protein biomarkers is an important tool for medical diagnostics, typically exploiting 
concentration of particular biomarkers or biomarker release from tissues. We sought to establish 
whether proteins not normally released by living cells can be extracted without harming cells, with a 
view to extending this into biomarker harvest for medical diagnosis and other applications. Styrene 
maleic acid (SMA) is a polymer that extracts nanodiscs of biological membranes (containing membrane 
proteins) from cells. Hitherto it has been used to harvest SMA-lipid-membrane protein particles 
(SMALP) for biochemical study, by destroying the living cellular specimen. In this study, we applied 
SMA at low concentration to human primary cardiovascular cells and rat vascular tissue, to ‘biopsy’ cell 
proteins while avoiding significant reductions in cell viability. SMA at 6.25 parts per million harvested 
proteins from cells and tissues without causing significant release of cytosolic dye (calcein) or reduction 
in cell viability at 24 and 72 hours post-SMA (MTT assay). A wide range of proteins were recovered 
(20–200 kDa) and a number identified by mass spectrometry: this confirmed protein recovery from 
plasma membrane, intracellular membranes and cell cytosol without associated cell death. These data 
demonstrate the feasibility of non-lethally sampling proteins from cells, greatly extending our sampling 
capability, which could yield new physiological and/or pathological biomarkers.
Current cell-based biopsy measurements rely on using destructive techniques to remove and isolate particu-
lar cellular components, especially those housed within a membrane environment. While these techniques can 
provide a useful approach for obtaining valuable information, with a view to obtaining specific biomarkers, a 
non-destructive means of actively isolating biomarkers would open avenues for new marker isolation techniques, 
thereby advancing disease diagnoses to earlier stages, or for safely obtaining information from small, irreplaceable 
cell samples.
We have examined the use of styrene maleic acid (SMA), an amphipathic polymer, in a previously unexplored 
context: to determine if it could obtain cell proteins while retaining cell viability, in effect to non-lethally ‘biopsy’ 
cells. A key motivation for this study was to identify if such a method could build on the rapid growth of research 
into exosomes1 and microvesicles2, specifically that driven by the recognition of their potential as diagnostic 
markers3,4. The detection of disease biomarkers, in terms of the disease phase detected by these markers, has 
advanced from the reactive detection of markers of cell destruction such as elevated cardiac troponin post-MI, 
to the prospective identification of disease markers that are released from cells in advance of symptoms3,4. The 
next level of advancing biomarker detection to an earlier stage of pathology would be to move from awaiting the 
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passive shedding of such markers from cells to a process of actively collecting them. Achieving this will require 
means to obtain such proteins, while also capturing them in a stable configuration to permit subsequent analysis.
Isolating membrane proteins has a number of significant challenges, not least removing them from the 
membrane environment and then maintaining them in a stable state once removed. Traditionally this has been 
achieved through a detergent-based approach with numerous types of detergents available with differing prop-
erties5. These allow for membrane proteins to be stabilised without the need for the lipid bilayer and subse-
quent biophysical characterisation by, for example X-ray crystallography, electron microscopy and NMR6. More 
recently, it has been demonstrated that SMA isolates membrane proteins from a membrane environment in stable 
disc-shaped nanoparticles7, allowing preservation of proteins or protein complexes in a more native state, with 
a ‘cuff ’ of lipid bilayer around the protein. Moreover, SMA-extracted proteins, as with those stabilised in more 
traditional detergents can be studied through a range of biophysical techniques8–10. This is applicable not only to 
bacterial membranes but has also been demonstrated to be successful for HEK cell membranes11.
Here we have investigated if an SMA approach could be applied to a range of cells for the extraction of mem-
brane proteins for biochemical studies, in a non-lethal process in contrast to the destructive nature of current 
techniques12. While previous explorations of SMA function have provided a novel and valuable tool in the bio-
chemical and structural biology context, this is to our knowledge the first demonstration of the ability of SMA to 
harvest proteins from cells non-lethally, most notably from human cells. Our first objective was to identify if such 
proteins could be retrieved from cells via SMA; if this proved successful, our second objective was to carry out a 
broad assessment of which proteins were sampled from cells and from which cellular locations, thereby obtaining 
a broad overview of the method’s potential for further utilisation. We elected to achieve these aims using human 
cells, to most rapidly assess validity for potential translational development. SMA was also able to recover proteins 
from intact tissue, in this case rat arterial blood vessel ex vivo, without causing apparent harm to the cells of the 
vessel.
Results
Application of SMA without significant cell death. The first objective was to determine whether there 
was an effective concentration range at which SMA could be applied to human cells without a significant impact 
on viability. To avoid misrepresentative results due to a particularly low vulnerability of one cell type, we exam-
ined two different types of primary cultured human cardiovascular cells in parallel: cardiac fibroblasts (CFs) 
and vascular smooth muscle cells (VSMCs), which were isolated according to our established methods13,14. A 
dual-assay approach was utilised to determine the impact of SMA on cell survival: cells were loaded with 10 µM 
calcein-AM prior to SMA application to determine impact on membrane integrity acutely, then MTT assays to 
determine cell viability were performed 24 hours post-SMA application to identify any delayed cell death. With 
a view to potential future applications of SMA cell ‘biopsy’ in both in vitro and in vivo contexts, a brief (but suf-
ficiently long to ensure consistency across repeats) application of SMA (10 minutes) was used. Using a range of 
SMA concentrations, from 1.25 to 25 parts per million (ppm), we demonstrated that SMA applied at or below 
6.25 ppm did not significantly reduce cell membrane integrity, as determined by the retention of calcein in the 
cell cytoplasm, in either cell type (Fig. 1a). Subsequent analysis using MTT assay confirmed no significant impact 
on cell viability 24 hours after SMA application at these levels (≤6.25 ppm; Fig. 1b) but with clear evidence of cell 
death at higher concentrations of SMA. Macroscopic appearances of cell phenotypes in culture were consist-
ent with these assay findings, with normal cell morphologies following exposure to 0 or 6.25 ppm SMA corre-
sponding to positive calcein staining (Fig. 1c). To exclude delayed cell death due to SMA application at or below 
6.25 ppm, MTT assay 72 hours after SMA application confirmed no reduced cell viability (Fig. 1d).
Low SMA concentration harvests proteins from cells. With a range of SMA concentrations thus iden-
tified as being sub-lethal to human cells, we then established whether this low-dose SMA application was also 
effective in sampling proteins from these cells. Firstly, VSMCs were biotinylated using a cell-impermeable biotin 
conjugation reagent before SMA application. SMA lipid particles (SMALP) obtained from cells by SMA applica-
tion were collected in suspension, then analysed for biotinylated proteins using SDS-PAGE and immunoblotting. 
Biotinylated proteins over a range of sizes (approximately 20 to 200 kDa) were present in collected suspensions 
following application of SMA from 25 ppm to 6.25 ppm (Fig. 2a,b). As expected, biotinylated proteins were also 
harvested from cells treated with the detergent Triton-X. However, only residual background signal was seen in 
samples obtained using physiological buffer (Dulbecco’s PBS) with 0% SMA, showing that shedding of biotiny-
lated proteins did not occur in the absence of SMA (Fig. 2a,b).
Suspensions were collected following 6.25 ppm SMA application to non-biotinylated cells, with staining of 
SDS-PAGE gels identifying a similar (20 to 200 kDa) range of proteins. This protein sampling was seen from 
both cell types across repetitions, but not in the 0% SMA (negative control: PBS only) samples (Fig. 2c). Levels of 
proteins sampled in PBS containing 0.01% Triton-X were also assessed for comparative purposes (Fig. 2c). The 
presence of SMALPs (with a distinctive discoid morphology) and the identity of proteins harvested therein was 
determined by electron microscopy and mass spectrometry respectively. In the absence of exposure to SMA, no 
SMALP particles were observed by electron microscopy (Fig. 2d) and only a single or no protein was recovered 
from either CFs or VSMCs (Suppl. Fig. 1). In contrast, exposure of either cell type to 6.25 ppm SMA for 10 min-
utes resulted in the detection of SMALP nanodiscs using electron microscopy, with particle appearances consist-
ent with SMALPs identified previously11 (Fig. 2d). Mass spectrometry identified in excess of 70 distinct proteins 
from each cell type, the characterisation of which was our next objective.
Mapping of SMA sampling to cellular locations and cell type. With the primary objective of protein 
sampling from human cells without significant cell death achieved, we carried out analysis of the proteins recov-
ered by SMA biopsy. Following application of SMA (6.25 ppm, 10 min) to cells, the SMA solution was collected 
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and SMALPs isolated from suspension by ultracentrifuge (110,000 g for 20 hours at 20 °C) and protein identities 
determined by mass spectrometry. Collected proteins were digested with trypsin in-solution and subjected to 
liquid chromatography-mass spectrometry: this identified an average of 73.0 ± 17.4 unique proteins per sample, 
in three separate experiments (Suppl. Fig. 1). Panther and GOrilla (Gene Ontology Consortium) were used to 
determine the most likely cellular location of UniProt-identified15 proteins recovered in the SMA biopsy. As we 
had anticipated, a large number of proteins were obtained from plasma membrane-associated cellular locations, 
particularly extracellular vesicles and exosomes, however an unexpected addition was that proteins were also 
obtained from intracellular vesicles and cytoskeletal locations (Fig. 3a,b). To explain these findings, STRING 
analysis of these data, which identifies likely protein-protein interactions in the protein set and thus allows 
more detailed understanding of protein sub-cellular location, was applied to the SMALPs from CFs (Fig. 3c) 
and VSMCs (Fig. 3d). This identified the cytoplasm, plasma membrane and actin-bound proteins as the most 
common origin of proteins recovered, perhaps suggesting that proteins other than transmembrane proteins are 
sampled by the SMA biopsy technique due to their interaction with membrane components via the cytoskeleton. 
Further STRING analysis identified a range of individual proteins known to be of extracellular vesicles and their 
protein-protein interactions, which were obtained from both CFs and VSMCs (Suppl. Fig. 2). While some of the 
proteins recovered by SMA biopsy were common across both cell types (including several heat-shock proteins: 
Figure 1. Low-dose styrene maleic acid can be applied to cells without significantly reducing viability. (a) 
Styrene maleic acid applied to human CFs or VSMCs for 10 minutes at 37 °C identified a range of concentrations 
that did not significantly reduce viability, with membrane integrity demonstrated by calcein-AM assay (ANOVA 
plus Tukey’s test *p < 0.05, **p < 0.01, n = 8). (b) Cell viability was confirmed 24 hours post-SMA application by 
MTT assay (ANOVA plus Tukey’s test **p < 0.01, n = 8). (c) Assay findings were consistent with morphological 
appearances on microscopy, with intact viable cells stained green with calcein-AM. (d) Cell viability for low-
dose SMA concentrations was re-confirmed 72 hours post-SMA application by MTT assay (ANOVA plus 
Tukey’s test, n = 6).
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HSPA8, HSPB1, HSP90AA and HSP90AB), proteins characteristic to CFs (vinculin, VCL, P18206) or VSMCs 
(Alpha actinin 4, ACTA2, P68032) were identified in the corresponding SMA biopsies, demonstrating that the 
repertoire of proteins receovered reflected the cell source to some extent (Fig. 3e).
SMA obtains proteins from tissue, without significant cell death. The final study objective was 
to confirm the efficacy of the SMA biopsy method when applied to intact tissue, using vascular tissue ex vivo. 
For this, adult Wistar rat aorta tissue samples were obtained, washed thoroughly with sterile Dulbecco’s PBS 
and 6.25 ppm SMA applied to the vessel interior for 10 minutes. The SMA biopsy method in ex vivo vessel also 
obtained a range of proteins, as identified by mass spectrometry, which were correlated with a similar range of 
cellular locations, namely extracellular vesicles and exosomes; external plasma membrane; lipoprotein particles 
(Panther and GOrilla analysis, Fig. 4a). Further STRING analysis of these proteins indicated the following sub-
cellular localisation: cytoplasm; plasma membrane; actin associated (Suppl. Fig. 3). Tissue images following dual 
nuclear staining with Hoechst 33342 (staining all nuclei) and propidium iodide (PI, staining dead cell nuclei only) 
showed cells were PI-negative in tissue after 6.25 ppm SMA biopsy procedure. This confirmed no impact on cell 
viability in treated tissue (Fig. 4b).
Discussion
We have determined that the application of SMA at 6.25 ppm (equal to ~1 µM) for 10 minutes sampled proteins 
of a broad range of sizes without causing significant cell death, thus demonstrating the efficacy of this technique 
as a cellular ‘biopsy’ tool. We have further demonstrated that SMA can retrieve proteins in different cell types 
and from intact tissue without significant cell death. The reagent is able to recover proteins from a wide range of 
sub-cellular locations, not only the plasma membrane but also the cytosol and actin-cytoskeleton, which further 
extends its capability as a biopsy tool. This therefore provides a novel tool to advance the detection of cell bio-
markers, from passive collection to the active retrieval of them from cells or intact tissue.
Using text mining, we determined that for CFs around 31% of identified proteins either contain a transmem-
brane domain or are directly associated with the plasma membrane, with another 32% of identified proteins 
Figure 2. Low-dose styrene maleic acid application effectively samples proteins from cells. (a) Labelling of 
cells with biotin prior to 6.25 ppm SMA application allowed confirmation with biotin immunoblotting of the 
presence of a range of proteins (20–200 kDa) in the obtained suspension. (b) Proteins were absent from the 
final post-biotinylation Dulbecco’s PBS cell wash, as confirmed across repetitions (ANOVA plus Tukey’s test 
*p < 0.05, **p < 0.01 compared to Dulbecco’s PBS wash control, mean ± SEM, n = 3). (c) Gel analysis of SMA 
suspensions demonstrated requirement of SMA for protein collection in CFs and VSMCs, with no detectable 
protein seen in 0% SMA (Dulbecco’s PBS), with 6.25 ppm SMA obtaining quantifiable protein samples from 
both cell types and levels of protein obtained by 0.01% Triton-X for comparison (ANOVA plus Tukey’s test 
*p < 0.05, **p < 0.01, box and whiskers plots showing median ± 95% CI, n = 3). (d) The presence of SMALP 
particles in 6.25 ppm SMA suspension obtained from VSMCs was confirmed by electron microscopy, compared 
with their absence in 0% SMA (PBS, bar = 150 nm).
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Figure 3. Mapping of cellular proteins and areas sampled by SMA biopsy. GO analysis of data identifying 
subcellular locations of all proteins sampled from (a) CFs (n = 3) and (b) VSMCs (n = 3), with consistent 
probabilities for locations of protein sampling in each cell population. (Colour code for GO maps, showing 
confidence of protein sampling from these locations: p > 10−3 white; p 10−3–10−5 beige; p 10−5–10−7 pale 
orange; p 10−7–10−9 dark orange; p < 10−9 red). (c) Mapping of known and predicted protein-protein 
interactions in SMA-biopsies from CFs by STRING analysis. Likely subcellular localisation indicated as follows: 
cytoplasm (purple, 93 proteins); plasma membrane (blue, 57 proteins); actin binding (yellow, 33 proteins). Line 
thickness indicates confidence of protein-protein interaction, a confidence threshold of 0.7 (high confidence) 
was used for all indicated interactions. (d) Mapping of known and predicted protein-protein interactions in 
SMA-biopsies from VSMCs by STRING analysis. Likely subcellular localisation indicated as follows: cytoplasm 
(purple, 115 proteins); plasma membrane (blue, 43 proteins); actin binding (yellow, 25 proteins). Line thickness 
indicates confidence of protein-protein interaction, a confidence threshold of 0.7 (high confidence) was used for 
all indicated interactions. (e) Heat map of proteins in SMA-biopsies specific to CFs (red) or VSMCs (blue) cells, 
and proteins sampled from both cell types (both colours).
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associated with the actin filament network. In VSMCs the numbers are similar: 31% of proteins contain trans-
membrane domains or are otherwise associated with the plasma membrane, whereas 26% of identified proteins 
are associated with the actin filament network. It is therefore likely that a substantial proportion of these proteins 
have either been sampled directly from the plasma membrane, or indirectly through association of the actin fila-
ment network with the plasma membrane.
Although previous work to achieve sampling of intact proteins from live cells has been carried out, this has 
to date only been achieved using laser dissection techniques16. Whilst elegant, the laser dissection approach is 
difficult to perform at scale, or to internal tissue structures. The achievement of protein sampling without exten-
sive cell destruction using a stable, widely-applicable chemical tool opens the door to possible in vivo or clinical 
utilisation of intact protein capture. To the best of our knowledge, this is the first demonstration of intact protein 
sampling while retaining cell viability by such a tool.
Most use of SMA to date, in the context of protein chemistry, has focused on its value for analyses of mem-
brane protein biology or structure: we had therefore expected plasma membrane proteins to be sampled in our 
study, as was indeed seen. However, the collection of proteins found in both peripheral (extracellular vesicles and 
exosomes) and more central (cytoskeleton, cytosolic and intracellular organelles) locations indicates that this 
technique potentially samples from a wider range of cellular areas than had been initially anticipated. This may 
offer a wider scope for the potential of SMA to sample cell biomarkers of development or dysfunction.
The explanation for the ability of SMA to sample proteins from such a wide range of locations is uncertain, 
although it is plausible that the obtained nanodiscs would include proteins adherent to their formerly-intracellular 
surface. This interpretation is supported by the presence in all SMA samples (from both CFs and VSMCs) of 
moesin (MSN, P26038; linking cytoskeletal structures with the plasma membrane) and of filamin A (FLNA, 
P21333; anchoring transmembrane proteins to the cytoskeleton).
Beyond this, the foundational data presented here, that this ‘biopsy’ technique can be effectively applied to 
intact tissue ex vivo without tissue disruption or cell viability loss, open the possibility of its use in an in vivo 
setting. The data presented here of tissues ‘biopsied’ by SMA ex vivo offer only a limited model of tissue response 
regarding potential in vivo SMA application, due to the substantial differences to the in vivo setting. It is however 
notable that this chemical (in anhydride form, combined with DMSO) has been used for many years as a contra-
ceptive agent17, at much higher concentrations than required for protein sampling in this study, with phase I and 
II human trials completed18,19.
While this technique sampled cell-specific proteins from each of the cell types examined, it was also identified 
that a broad range of proteins were consistently sampled from both cell types. Notably, several proteins which 
have been identified as possible disease biomarkers (HSPA820, HSPB121, HSP90AA22 and HSP90AB23) were found 
to be consistently sampled in both cell types. This suggests that this technique could obtain these potential bio-
markers from target cell populations also, for the diagnosis or staging of disease.
The novel biopsy technique opens a new avenue towards the recovery of useful biomarker information from 
cells and tissues. It is well known that other amphipathic polymers of related structure exist, which also harvest 
proteins from biological membranes24,25. It is entirely possible that these polymers could biopsy in a similar way 
to SMA, but may recover a different repertoire of proteins from the specimen. This would further extend the 
potential of the technique demonstrated here.
Figure 4. SMA application to intact tissue ex vivo was non-toxic and obtained a range of proteins. Mass 
spectrometry confirmed successful sampling of proteins from ex vivo rat aorta following 10 min exposure 
to 6.25 ppm SMA, with (a) Gorilla (GO) mapping of proteins with subcellular locations identifying proteins 
linked with: extracellular vesicles and exosomes; external plasma membrane; lipoprotein particles. (Colour 
code for GO map, showing confidence of protein sampling from these locations: p > 10−3 white; p 10−3–10−5 
beige; p 10−5–10−7 pale orange; p 10−7–10−9 dark orange; p < 10−9 red). (b) The non-toxicity of the SMA 
sampling technique in intact tissue was confirmed by Hoechst (blue) and propidium iodide (red) dual-staining 
of aorta after 10 min application of 6.25 ppm SMA, compared to vehicle (PBS) or known toxin (PI + ve ctrl) 
(bar = 100 µm).
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The ability to exploit this protein sampling technique, which has been demonstrated for the first time here 
in both cells and tissue, by directing its use towards the detection of pathological markers at a preclinical stage, 
could be of immense value. The potential to form a personalised evidence-based stratification of individual risk 
could be utilised for a range of common and severe diseases, with the vascular complications of diabetes mellitus 
a representative example.
Methods
Human tissue sample collection. Primary human cardiovascular cells of two types were examined: car-
diac fibroblasts and vascular smooth muscle cells, each isolated from donated samples of human tissue. Ethical 
approval was obtained from the NHS Health Research Authority: Yorkshire and the Humber - Leeds West 
Research Ethics Committee (reference CA01/040), with all procedures carried out in accordance with local and 
national guidelines and regulations. Informed donor consent was obtained for the use of each human tissue 
sample.
Cardiac fibroblast isolation. The CFs were isolated from myocardial tissue samples, obtained during the 
routine progress of cardiac bypass surgery in adult patients. Samples were digested and the cells of interest iso-
lated according to established methods13, prior to being maintained and examined in vitro as adherent cells.
In brief, myocardial tissue underwent mincing, followed by digestion. Digestion of tissue was achieved by 
incubation with 800 U/ml collagenase type II solution (Worthington Biochemical Corporation, Lakewood, 
NJ, USA) in Dulbecco’s modified Eagle medium (DMEM) containing 0.05% bovine serum albumin (BSA) for 
4 hours at 37 °C. Cells were pelleted by centrifugation, washed with DMEM/BSA, and re-suspended in full growth 
medium. Cells were then plated onto cell culture flasks in a humidified incubator at 37 °C, 5% CO2 for 30 minutes, 
allowing CFs to adhere to culture vessels. After this, all non-adherent cells were removed and experiments per-
formed on early passage cells.
Vascular smooth muscle cell isolation. Tissue samples were long saphenous vein pieces, obtained during 
the routine progress of cardiac bypass surgery in adult patients. Samples were then dissected and the cells of inter-
est isolated according to established methods14, prior to being maintained in vitro as adherent cells.
In brief, VSMCs were obtained by producing vein tissue explants approximately 1 mm3 in size, then main-
tained in medium (as described below) in a humidified incubator at 37 °C, 5% CO2 for 1–2 weeks. After this time, 
VSMCs were seen to be migrating from explants. Explants were then maintained for another 2–3 weeks and cells 
passaged with remaining explant tissue discarded. Cell phenotype was confirmed by immunostaining.
cell culture. Both CFs and VSMCs were plated and maintained in the following medium: Dulbecco’s 
Modified Eagles’ Medium (DMEM, cat. no. 21969); 10% Foetal Calf Serum (FCS); 1% Glutamax; 1% 
Penicillin-Streptomycin; 0.1% Fungizone (all Life Technologies; percentages v/v). Plating densities and mainte-
nance conditions were consistent for both cell types. Cells were plated at densities of: 20,000 cells/well in 24-well 
plates for viability assays, or 80,000 cells/well in 6-well plates for protein sampling. Cell were maintained prior to 
experiments in a humidified incubator at 37 °C, 5% CO2.
Rat tissue isolation. For samples of intact vascular tissue, 200 g male Wistar rat aortas were freshly obtained 
after sacrifice (animals sacrificed by Home Office Schedule 1-approved methods). Tissue was dissected out from 
the proximal arch to the aortic bifurcation and washed thoroughly in sterile Dulbecco’s PBS. All sacrifice methods 
were carried out in accordance with Home Office guidelines and regulations for procedures involving protected 
species. No protocols were carried out on animals before sacrifice.
tissue culture. For cell viability studies, rat aorta was cut into 1 cm lengths after washing and cut along the 
length to expose the interior lumen surface of the vessel. Explanted rat aorta tissue samples (1 cm length) were 
maintained in medium as for cultured human cells, but with supplement of medium with 30% FCS26. Tissue 
segments were maintained in 24-well plates prior to experiments in a humidified incubator (37 °C, 5% CO2) prior 
to use in assays.
Styrene maleic acid application. Stock SMA solution, 2.3:1 ratio, 25% concentration (w/v) (SL30010), 
was obtained from Polyscope polymers B.V. (Geleen, the Netherlands). This was applied to cells at final concen-
trations ranging from 1.25 to 25 ppm, diluted in Dulbecco’s PBS containing Ca2+ and Mg2+ (Life Technologies) 
immediately before application. These concentrations were applied to both human cell culture treatments and in 
rat aorta tissue viability studies. SMA applications were performed for 10 minutes in a Binder humidified tissue 
culture incubator (37 °C, 5% CO2). To provide a positive control for cell membrane lysis, 0.01% Triton-X 100 in 
Dulbecco’s PBS (v/v) was applied to cells or tissue segments (for 10 minutes under the same conditions as for SMA 
application). For full length dissected rat aorta, tissue samples were rinsed and maintained in tissue culture grade 
Dulbecco’s PBS, followed by 10 minutes recycled 5 ml solution ‘flush’ biopsy with SMA or Dulbecco’s PBS for SMA 
biopsy and control respectively, and staurosporine for cytotoxicity-positive control.
The SMALP nanodisc suspensions containing sampled proteins were aspirated and placed on ice for immedi-
ate use, or were stored at −80 °C for later analysis.
Assays of membrane integrity and cell viability. Medium was replaced with 10 µM calcein-AM 
(GeneCopoeia) in DMEM for 30 minutes, in a humidified incubator (37 °C, 5% CO2), before medium was aspi-
rated and cells washed with Dulbecco’s PBS to remove all extracellular calcein-AM and medium. Cells were 
treated with a range of SMA concentrations as described, then returned to normal culture medium. For analysis, 
cells were placed in a fluorometric scanner (Varioskan Flash; excitation 495 nm, emission 515–525 nm).
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For MTT assay of cell viability, cells were returned to normal culture medium after SMA treatment and main-
tained in a humidified incubator for 24 or 72 hours (37 °C, 5% CO2). After this, 0.5 mg/ml MTT (Sigma) in culture 
medium was applied for 60 minutes (37 °C, 5% CO2), then the cells lysed by applying solubilising solution (4% 
1 M HCl in propan-2-ol/isopropyl alcohol, 300 µl/well) and pipetted thoroughly: this lysed cells and distributed 
the crystals formed by the MTT reagent as previously described27. The plate was then transferred to a Varioskan 
Flash plate reader and absorbance recorded at 570 nm (with reference absorbance 630 nm).
SDS-pAGe. The optimal SMA concentration for cell protein sampling (6.25 ppm) was used to collect pro-
teins within SMALP nanodiscs from biotinylated cells, using a cell-impermeable biotinylation reagent. Cells were 
biotinylated with 0.2 mg/ml biotin-XX SSE/DMSO (Life Technologies) in Dulbecco’s PBS (without Ca2+ and 
Mg2+) at room temperature. Protein-SMA samples were mixed with sample loading buffer (0.23 M Tris–HCl 
pH 6.8, 24% v/v glycerol, 120 μM bromophenol blue, 0.4 M DTT, 0.23 M SDS), containing protease inhibitors 
and 2-mercaptoethanol. This mixture was incubated for 30 minutes at 37 °C then loaded onto SDS-PAGE gels. 
Proteins were run through 4% stacking gel at 50 V for 20 min, then through 10% resolving gel at 100 V for 2 hours. 
Biotinylated proteins were identified by Western blotting: by transferring to membranes with methanol, blocking 
with 5% BSA (Sigma, UK) and incubating with streptavidin-poly HRP (Sigma) in 5% BSA solution. This was 
followed by electrochemical luminescent (Thermo-Fisher) detection of HRP. Non-biotinylated protein bands 
were visualised either using protein staining of gels with InstantBlue solution (Expedeon), or used for in-solution 
mass spectrometry analysis.
In-gel protein staining of samples was quantified using AIDA Image Analyser (Raytest), with these data ana-
lysed to confirm equal variances (Brown-Forsythe test) and normal distribution (Shapiro-Wilk test) as part of 
ANOVA analysis.
Mass spectrometry. Collected SMA samples were centrifuged at 110,000 g for 20 hours at 20 °C in a bench-
top ultracentrifuge (Beckman Coulter), to concentrate six-fold. Samples were reduced (10 mM DTT, 1 hour at 
57 °C), alkylated (55 mM iodoacetamide, 30 min in the dark) and digested with trypsin (protease to substrate ratio 
of 1:50, 18 hours at 37 °C). Digested samples were then analysed using an ACQUITY M-Class Ultra-high Pressure 
Liquid Chromatographer coupled with a Xevo QToF G2-XS mass spectrometer (Waters UK, Manchester). LC 
separation of the peptide mixtures was performed on an ACQUITY M-Class UPLC (Waters UK, Manchester). 
1 µl of each sample was loaded onto a Symmetry C18 trap column (180 µM i.d. * 20 mm) and washed with 1% 
acetonitrile/0.1% formic acid for 5 min at 5 µl min−1. After valve switching, the peptides were then separated on 
a HSS T3 C18, 75 µm i.d. × 150 mm analytical column (Waters UK, Manchester) by gradient elution of 1–60% 
solvent B in A over 30 min. at 0.3 µl min−1. Solvent A was 0.1% formic acid in water, solvent B was 0.1% formic 
acid in acetonitrile. The column eluant was directly interfaced to a quadrupole orthogonal time of flight mass 
spectrometer (Xevo QTOF G2-XS, Waters UK, Manchester) via a Z-spray nanoflow electrospray source. The 
MS was operated in positive TOF mode using a capillary voltage of 3.0 kV, cone voltage of 40 V, source offset of 
80 V. The source temperature was 80 °C. Mass calibration was performed using [Glu]-fibrinopeptide (GFP) at 
a concentration of 250 fmol µl−1. GFP was also used as a lock mass calibrant with a one second lock spray scan 
taken every 30 s during acquisition. Ten scans were averaged to determine the lock mass correction factor. Data 
acquisition was using data dependent analysis with a 0.2 s scan MS over m/z 350–2000 being followed by five 
0.5 s MS/MS (m/z 50–2000) taken of the four most intense ions in the MS spectrum. CE applied was dependent 
upon charge state and mass of the ion selected. Dynamic exclusion of 60 s was used. Data processing was per-
formed using the MassLynx v4.1 suite of software supplied with the mass spectrometer. Peptide MS/MS data were 
processed with PEAKS Studio (Bioinformatic Solutions Inc., Waterloo, Ontario, Canada) and searched against 
the Uniprot database (release 2018_02) with entries confined to reviewed records of the appropriate genus. 
Carbamiodomethylation was selected as a fixed modification, variable modifications were set for oxidation of 
methionine and deamidation of glutamine and asparagine. MS mass tolerance was 20 ppm, and fragment ion 
mass tolerance was 0.05 Da. The false discovery rate was set to 1%.
Protein identification was carried out using Uniprot and protein localisation with Panther/GOrilla (Multi 
Knowledge Project, http://cbl-gorilla.cs.technion.ac.il/). Sample proteomes, as obtained from mass spectrom-
etry, were analysed using GOrilla software to identify the enrichment of protein components from particular 
cellular locations. Swiss-Prot provided information on cell locations of proteins, thus establishing confidence of 
our sampling in different locations. Swiss-Prot reviewed proteomes: 20,192 human proteins as of June 21, 2017 
(reviewed: yes AND organism: “Homo sapiens (Human) [9606]” AND proteome: up000005640) and 8,017 rat 
proteins as of November 21, 2017 (reviewed: yes AND organism: “Rattus norvegicus (Rat) [10116]” AND pro-
teome: up000002494). Protein-protein interactions and their subcellular localisation were subsequently analysed 
by STRING28.
electron microscopy. Suspensions of SMA and sampled proteins were prepared as previously described 
in the methods. The negative stain procedure is as described previously29. Briefly, 3 µl of suspension was applied 
to a carbon coated grid which had been glow discharged for 30 seconds. Following this, the protein solution was 
blotted before the addition of 3 µl uranyl acetate solution (2%) which was left for 1 minute before blotting and 
the addition of another 3 µl uranyl acetate solution (2%). The grid was then blotted and air dried before imaging. 
Grids were imaged at a nominal magnification of 49,000 using a FEI Tecnai T12 microscope, operating at 120 Kv 
fitted with a Gatan Ultrascan 4000 CCD camera.
Data availability
The datasets generated during and analysed during the current study are available from the corresponding author 
on reasonable request.
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